Navana Pharmaceuticals Statistics

Total Valuation

Navana Pharmaceuticals has a market cap or net worth of BDT 5.35 billion. The enterprise value is 10.38 billion.

Market Cap	5.35B
Enterprise Value	10.38B

Important Dates

The last earnings date was Tuesday, October 22, 2024.

Earnings Date	Oct 22, 2024
Ex-Dividend Date	Nov 20, 2024

Share Statistics

Navana Pharmaceuticals has 107.42 million shares outstanding. The number of shares has increased by 16.28% in one year.

Current Share Class	n/a
Shares Outstanding	107.42M
Shares Change (YoY)	+16.28%
Shares Change (QoQ)	+0.36%
Owned by Insiders (%)	35.49%
Owned by Institutions (%)	n/a
Float	69.30M

Valuation Ratios

The trailing PE ratio is 13.21.

PE Ratio	13.21
Forward PE	n/a
PS Ratio	0.77
PB Ratio	1.17
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 8.60, with an EV/FCF ratio of -16.61.

EV / Earnings	25.66
EV / Sales	1.50
EV / EBITDA	8.60
EV / EBIT	10.47
EV / FCF	-16.61

Financial Position

The company has a current ratio of 0.87, with a Debt / Equity ratio of 1.18.

Current Ratio	0.87
Quick Ratio	0.20
Debt / Equity	1.18
Debt / EBITDA	4.45
Debt / FCF	-8.60
Interest Coverage	2.04

Financial Efficiency

Return on equity (ROE) is 9.06% and return on invested capital (ROIC) is 6.65%.

Return on Equity (ROE)	9.06%
Return on Assets (ROA)	5.93%
Return on Capital (ROIC)	6.65%
Revenue Per Employee	1.67M
Profits Per Employee	97,667
Employee Count	4,143
Asset Turnover	0.66
Inventory Turnover	2.09

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -38.14% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-38.14%
50-Day Moving Average	52.63
200-Day Moving Average	80.75
Relative Strength Index (RSI)	51.27
Average Volume (20 Days)	375,483

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Navana Pharmaceuticals had revenue of BDT 6.90 billion and earned 404.63 million in profits. Earnings per share was 3.77.

Revenue	6.90B
Gross Profit	3.14B
Operating Income	991.84M
Pretax Income	516.25M
Net Income	404.63M
EBITDA	1.21B
EBIT	991.84M
Earnings Per Share (EPS)	3.77

Full Income Statement

Balance Sheet

The company has 267.77 million in cash and 5.38 billion in debt, giving a net cash position of -5.03 billion or -46.85 per share.

Cash & Cash Equivalents	267.77M
Total Debt	5.38B
Net Cash	-5.03B
Net Cash Per Share	-46.85
Equity (Book Value)	4.56B
Book Value Per Share	42.60
Working Capital	-814.39M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 707.30 million and capital expenditures -1.33 billion, giving a free cash flow of -625.10 million.

Operating Cash Flow	707.30M
Capital Expenditures	-1.33B
Free Cash Flow	-625.10M
FCF Per Share	-5.82

Full Cash Flow Statement

Margins

Gross margin is 45.59%, with operating and profit margins of 14.38% and 5.87%.

Gross Margin	45.59%
Operating Margin	14.38%
Pretax Margin	7.48%
Profit Margin	5.87%
EBITDA Margin	17.50%
EBIT Margin	14.38%
FCF Margin	-9.06%

Dividends & Yields

This stock pays an annual dividend of 1.40, which amounts to a dividend yield of 2.81%.

Dividend Per Share	1.40
Dividend Yield	2.81%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	2
Payout Ratio	33.83%
Buyback Yield	-16.28%
Shareholder Yield	-13.47%
Earnings Yield	7.57%
FCF Yield	-11.69%

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	n/a